Nontuberculous Mycobacteria (NTM), Bronchiectasis and COVID-19: Research and Treatment Update

Nontuberculous mycobacteria (NTM), a non-contagious cousin of tuberculosis, is showing a marked increase in the U.S. population in recent years. Many of these patients also end up developing bronchiectasis, a condition that inhibits the ability to naturally clear mucous and bacteria from the airways and puts individuals at ever-increasing risk of infection. Find out how COVID-19 is impacting these patients and learn about current and future NTM and bronchiectasis research and treatments. To sign up for future Dialogue with a Doc discussions, please visit njhealth.org/DocSeries

Dr. Daley
https://www.nationaljewish.org/doctor...

Dr. Kasperbauer
https://www.nationaljewish.org/doctor...

Nontuberculous mycobacteria (NTM) https://www.nationaljewish.org/condit...

COVID-19 Information
https://www.nationaljewish.org/patien...

• #nonprofits_activism
• #covid_19
• #coronavirus
• #coronavirus_treatment
• #covid_19_nontuberculous_mycobacteria
• #ntm
• #ntm_treatment_guidelines
• #bronchiectasis
• #respiratory_illness
• #respiratory_disease
• #lung_disease
• #covid_19_antibody_testing
• #antiviral_therapy
• #covid_19_testing